WLL Reddit Mentions | ChartExchange

You’re very optimistic because it has about an 85% chance of being approved by FDA on November 22 we’re still quite a little bit away from November 22 so there’s gonna be a little bit of volatility
Also, for the illness that this drug help there is no other drug on the market for it
**Upcoming U.S. FDA Decision (PDUFA Date)**
**Target Action Date: The FDA's Priority Review for the MOLBREEVI Biologics License Application (BLA) is tracking toward a target action date of November 22, 2026.**
**Regulatory Momentum: The review follows strong Phase 3 data demonstrating continuous long-term improvements in patient lung function and respiratory health-related quality of life.**
**2. International Regulatory Pipeline**
**Europe and the U.K.: Marketing Authorization Applications (MAAs) are actively under review abroad. The U.K.'s MHRA decision is anticipated in Q4 2026, and the European Medicines Agency (EMA) decision is expected in Q1 2027.**
**3. Solid Financial Runway & Launch Capital**
**Cash Position: Savara reported approximately $173 million in cash, cash equivalents, and short-term investments.**
**Non-Dilutive Funding: In addition to current reserves, the company is positioned to secure up to $150 million in non-dilutive capital triggered upon the potential FDA approval of MOLBREEVI, heavily supporting their upcoming commercial build-out without immediate dilution pressure.**
**4. Extended Patent Protections**
**Global Intellectual Property: The European and Australian patent offices recently granted patents covering the liquid formulation of MOLBREEVI, securing market protection in those regions through March 2041.**
**5. Ongoing Scientific Validation**
**Global Presentation Stage: Positive long-term Phase 3 trial results continue to receive high-profile visibility, including encore presentations featured at the European Respiratory Society (ERS) Congress**
**The IMPALA Trial (Phase 2/3)**
**Design & Scope: A 24-week randomized, double-blind, placebo-controlled trial involving 138 patients across 18 countries, making it the largest controlled study in this rare disease at the time.**
**Performance: The trial successfully established proof of concept, demonstrating that inhaled molgramostim improved lung gas transfer and addressed the underlying pathophysiology of aPAP. These positive results served as the foundation for advancing into a larger pivotal trial and were published in the** ***New England Journal of Medicine*** **(NEJM).**
**2. The IMPALA-2 Pivotal Trial (Phase 3 Double-Blind Period)**
**Design & Scope: A 48-week global, double-blind, placebo-controlled trial enrolling 164 patients across 16 countries, establishing it as the largest controlled clinical trial ever conducted in aPAP.**
**Performance:**
**Primary Endpoint Met: Demonstrated statistically significant improvement in pulmonary gas transfer (measured by DLco%) compared to placebo at Week 24.**
**Surfactant Reduction: Showed a significant reduction in radiological surfactant burden (ground-glass opacification scores).**
**Fewer Lavages: Significantly fewer patients in the molgramostim group required invasive whole lung lavages (WLL) compared to the placebo group.**
**Quality of Life: Yielded clear improvements in respiratory health-related quality of life (SGRQ scores) and breathing metrics. These results were also published in the NEJM.**
**3. The IMPALA-2 Open-Label (OL) Extension Trial**
**Design & Scope: An ongoing long-term extension phase where all qualifying patients (including those who crossed over from the initial placebo group) receive daily molgramostim.**
**Performance:**
**Exceptional Retention: Achieved an outstanding 94% retention rate, with virtually all patients completing the double-blind period opting to continue into the long-term study.**
**Sustained Durability: Long-term data confirmed that patients on continuous molgramostim experienced continuous, sustained improvements in lung function and quality of life over extended periods.**
**Crossover Benefits: Patients who initially received a placebo during the double-blind period showed rapid and measurable clinical improvements once they switched over to active molgramostim treatment.**
**Overall, the data across these trial phases have consistently reinforced the drug's safety profile and ability to alter the disease course, driving strong regulatory momentum toward commercial approval.**
**There are currently no FDA-approved pharmaceutical drugs on the market specifically to treat autoimmune pulmonary alveolar proteinosis (aPAP).**
**Because no targeted drug therapy has existed, the historical standard of care has been physically managing the disease rather than treating it medically:**
**Whole Lung Lavage (WLL): Patients have traditionally had to undergo an invasive, surgical-level procedure where they are placed under general anesthesia, and one lung at a time is literally washed out with large volumes of saline to manually flush away the dangerous accumulation of protein and lipid buildup (surfactant).**
**Supportive Care: Beyond mechanical lung washing, treatment has mostly been limited to monitoring and supplemental oxygen when gas transfer becomes severely impaired.**
**If approved, MOLBREEVI will be a historic breakthrough as the very first approved drug therapy for aPAP, shifting the entire paradigm from invasive mechanical washing in a hospital to a targeted daily medication that addresses the root cause of the immune malfunction.**
**MOLBREEVI is approved, Savara will have a temporary monopoly—or exclusive legal rights—to sell it, meaning no other company can immediately jump in and sell a competing version.**
**That exclusive market position is secured through two main legal shields:**
**1. Orphan Drug Exclusivity (7 Years)**
**Because aPAP is a rare disease, the FDA granted MOLBREEVI Orphan Drug Designation.**
**Once an orphan drug is officially approved, the FDA grants a 7-year period of market exclusivity in the U.S.**
**During those 7 years, the government legally cannot approve any other company's version of the exact same drug for aPAP unless that competitor can prove their product is clinically superior.**
**2. Strong Patent Protections (Through 2041)**
**Beyond government exclusivity rules, Savara has actively built a wall around its intellectual property.**
**They hold patents covering the specific liquid formulation and delivery method of the drug that stretch out as far as March 2041 in major international markets.**
**These patents prevent generic or rival pharmaceutical companies from copying the formula and selling a generic alternative.**
**What This Means**
**Because there are currently no other pharmaceutical competitors on the market for aPAP, winning approval essentially gives Savara the exclusive right to define and serve this entirely new treatment category for years to come.**
Has this company met an exceeded all expectations from the FDA? For approval.